نتایج جستجو برای: drug companies

تعداد نتایج: 665185  

Journal: :P & T : a peer-reviewed journal for formulary management 2017
Stephen Barlas

Drug companies worry about new FDA "totality of evidence" standard.

Journal: :P & T : a peer-reviewed journal for formulary management 2013
Stephen Barlas

Drug companies push to rein in 340B discount drugs.

Journal: :Clinical journal of oncology nursing 2008
Patricia A Weiss

Myth: Insurance companies are not responsible for charges if a patient is in a clinical trial. This issue continues to be a focus of debate and contention among insurance companies, sponsoring agencies, and the treating site. Answer: Payment responsibility for patients in a clinical trial has been an ongoing source of contention between the sponsoring company and patients’ health insurance. Som...

Journal: :Drug metabolism and disposition: the biological fate of chemicals 2017
Niresh Hariparsad Diane Ramsden Jairam Palamanda Joshua G Dekeyser Odette A Fahmi Jane R Kenny Heidi Einolf Michael Mohutsky Magalie Pardon Y Amy Siu Liangfu Chen Michael Sinz Barry Jones Robert Walsky Shannon Dallas Suresh K Balani George Zhang David Buckley Donald Tweedie

The European Medicines Agency (EMA), the Pharmaceutical and Medical Devices Agency (PMDA), and the Food and Drug Administration (FDA) have issued guidelines for the conduct of drug-drug interaction studies. To examine the applicability of these regulatory recommendations specifically for induction, a group of scientists, under the auspices of the Drug Metabolism Leadership Group of the Innovati...

2009
Oktie Hassanzadeh Anja Jentzsch Bo Andersson Susie Stephens Eli Lilly Christian Bizer

Advances in the biological sciences are allowing pharmaceutical companies to meet the health care crisis with drugs that are more suitable for preventive and tailored treatment, thereby holding the promise of enabling more cost effective care with greater efficacy and reduced side effects. However, this shift in business model increases the need for companies to integrate data across drug disco...

2011
D Sreedhar MD Janodia VS Ligade

healthcare and Ranbaxy have been bought by Abbott and Daiichi Sankyo, respectively.[3] Cipla, an indigenous company, lone with a market share of about 5.4% tops the list of top 10 companies in India. The increasing presence of foreign companies among the top pharmaceutical companies in India is may be due to a few buyouts which happened in the recent past. Daiichi Sankyo, a leading Japanese pha...

Journal: :P & T : a peer-reviewed journal for formulary management 2009
Stephen Barlas

cept for this important fact: the exemption required companies to submit promotional material to the FDA before distributing it and to apply to the FDA for a supplemental New Drug Application (NDA) for the unapproved use. These two requirements have been eliminated in the new guidance—an omission that has greatly disturbed P&T committees and public inter est groups; these groups see the strippe...

Journal: :PLoS Medicine 2007
Adriane Fugh-Berman Shahram Ahari

In 2000, pharmaceutical companies spent more than 15.7 billion dollars on promoting prescription drugs in the United States [2]. More than 4.8 billion dollars was spent on detailing, the one-on-one promotion of drugs to doctors by pharmaceutical sales representatives, commonly called drug reps. The average sales force expenditure for pharmaceutical companies is $875 million annually [3]. Unlike...

2003
Sudip K. Das

Formulation, Fill & Finish 2003 10 he technologies behind oral drug delivery have emerged from the mainstream pharmaceutical industry and have become influential forces in their own right, as evidenced by the burgeoning “drug delivery companies” that are at the forefront of innovation and hold their own niche market. Drug delivery companies and their pharmaceutical industry partners are poised ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید